-
Biotech Industry Intelligence2 weeks ago
Former Acorda CEO Ron Cohen emerges at Parkinson’s cell therapy biotech Oryon
Former Acorda CEO Ron Cohen emerges at Parkinson’s cell therapy biotech Oryon
-
Uncategorized2 weeks ago
Pfizer ‘Confident’ in Valneva-Partnered Lyme Vaccine Despite Missed Primary Endpoint
The multivalent candidate, being developed by Pfizer and French partner Valneva under a 2020 pact, generated higher than 73% efficacy against the tick-borne disease in a...
-
Uncategorized2 weeks agoRoche leads AI drug discovery with new NVIDIA deal
Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totalling more than 3,500 GPUs, following an expansion of its global AI infrastructure. The company...
-
AI & Machine Learning in Biotechnology2 weeks agoSTAT+: Epic says it has uncovered rot in patient record sharing. Will HHS act?
In a recent court filing, electronic health records giant Epic Systems proved one of health care providers’ worst fears: Companies are posing as providers to gain...
-
Fierce Biotech2 weeks ago
MRI providers keep eye on rising helium prices amid war in Iran
Qatar’s exports of natural gas and helium—the latter essential for MRI scans—were effectively halted after Iran closed the Strait of Hormuz and attacked one of the...
-
BioPharma Dive – AI / Data2 weeks agoFDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares
Industry executives can share their views on the “national priority” program at a June meeting. Elsewhere, Sanofi licensed a T cell engager and Acorda’s former CEO...
-
Endpoints News2 weeks ago
CEO and C-suite are out in battle for control of Aurinia
Biotech takeover specialist Kevin Tang is consolidating control at Aurinia Pharmaceuticals, and has replaced the CEO and C-suite at the company, according to a securities filing...
-
Endpoints News2 weeks ago
Dizal’s first-line lung cancer data; Sanofi expands in China
Plus, news about Opdivo: 📊 Dizal drug succeeds in Phase 3 lung cancer study: The drug Zegfrovy improved progression-free survival compared to chemo in first-line non-small...
-
Fierce Biotech2 weeks ago
Merck hands over $20M in IBD drug target deal with Flagship’s Quotient
Looking to devise new drug targets for inflammatory bowel disease, Merck will pay Flagship Pioneering’s Quotient Therapeutics $20 million upfront for access to the biotech’s somatic...
-
STAT News – Biotech2 weeks agoSTAT+: Pharmalittle: We’re reading about Iran war’s impact on pharma supply chain, a Pfizer Lyme vaccine, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and...
High-Throughput Platform for Fast-Acting Covalent Protein Therapies
Terns rebuffed a higher bid before selling to Merck
